Literature DB >> 17363751

Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART).

Takashi Uzu, Makoto Sawaguchi, Hiroshi Maegawa, Atsunori Kashiwagi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363751     DOI: 10.2337/dc06-2493

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  15 in total

1.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

Review 2.  Comparing angiotensin II receptor blockers on benefits beyond blood pressure.

Authors:  Helmy M Siragy
Journal:  Adv Ther       Date:  2010-06-03       Impact factor: 3.845

Review 3.  Historical chronology of basic and clinical research in diabetic nephropathy and contributions of Japanese scientists.

Authors:  Jun Wada; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2009-04-11       Impact factor: 2.801

Review 4.  Valsartan: more than a decade of experience.

Authors:  Henry R Black; Jacqueline Bailey; Dion Zappe; Rita Samuel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 5.  Microalbuminuria as a target to improve cardiovascular and renal outcomes in diabetic patients.

Authors:  Seema Basi; Julia B Lewis
Journal:  Curr Diab Rep       Date:  2007-12       Impact factor: 4.810

6.  The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients.

Authors:  Kevin E C Meyers; Kenneth Lieberman; Susan Solar-Yohay; Guangyang Han; Victor Shi
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-14       Impact factor: 3.738

Review 7.  Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.

Authors:  P Vejakama; A Thakkinstian; D Lertrattananon; A Ingsathit; C Ngarmukos; J Attia
Journal:  Diabetologia       Date:  2011-12-22       Impact factor: 10.122

8.  Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

Authors:  E Imai; J C N Chan; S Ito; T Yamasaki; F Kobayashi; M Haneda; H Makino
Journal:  Diabetologia       Date:  2011-10-13       Impact factor: 10.122

9.  Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).

Authors:  Enyu Imai; Masakazu Haneda; Tetsu Yamasaki; Fumiaki Kobayashi; Atsushi Harada; Sadayoshi Ito; Juliana C N Chan; Hirofumi Makino
Journal:  Hypertens Res       Date:  2013-09-12       Impact factor: 3.872

10.  Renoprotective effects of telmisartan after unilateral renal ablation in rats.

Authors:  Tomohiro Matsuo; Yasuyoshi Miyata; Yuji Sagara; Yoshikazu Higami; Shohei Tobu; Manabu Matsuo; Mitsuru Noguchi; Isao Shimokawa; Hiroshi Kanetake; Hideki Sakai
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.